Inhibiting Growth of Human Triple-Negative Breast Cancer Cells by Activating Mutant p53 Protein Alone or in Combination With a Phosphatidylserine-Targeting Antibody

Triple-negative human breast cancers (TNBC) lack three proteins commonly targeted by chemotherapy; estrogen and progesterone receptors, and her-2-neu. Most current protocols used to treat TNBC are largely ineffective and aggressive tumors frequently re-emerge, leading to metastasis and patient death...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yayun, Brekken, Rolf A, Hyder, Salman M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089338/
http://dx.doi.org/10.1210/jendso/bvab048.2093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089338/
http://dx.doi.org/10.1210/jendso/bvab048.2093

Ejemplares similares